SIRPA and cancer: Current studies have revealed that monoclonal antibodies targeting CD47 and SIRPα show therapeutic effect in preclinical models of many solid tumors and hematological tumors by promoting macrophage phagocytosis on cancer cells and cancer stem cells, as a new way of tumor immunotherapy [19, 20].